Prosensa Therapeutics B.V.
Overview
Prosensa Therapeutics B.V. is a biotechnology company that was acquired by BioMarin Pharmaceutical Inc. in 2014. The company specializes in the development of RNA-modulating therapeutics for the treatment of genetic disorders, with a focus primarily on rare diseases like Duchenne muscular dystrophy.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Prosensa Therapeutics B.V. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.